Perrigo Co. (NASDAQ:PRGO) delivered a profit and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 1.45%.
Perrigo Co. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased 0.71% to $1.42 in the quarter versus EPS of $1.41 in the year-earlier quarter.
Revenue: Rose 18.22% to $919.8 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Perrigo Co. reported adjusted EPS income of $1.42 per share. By that measure, the company missed the mean analyst estimate of $1.44. It missed the average revenue estimate of $935.44 million.
Quoting Management: Perrigo’s Chairman and CEO Joseph C. Papa commented, “We are very pleased with our performance, as the team delivered all-time record quarterly revenue and adjusted diluted earnings per share. It was a very busy quarter for the team. We signed and closed the acquisition of Rosemont Pharmaceuticals, a specialty and generic prescription pharmaceutical company focused on the manufacturing and marketing of oral liquid formulations. We shipped Guaifenesin 600mg Extended-Release tablets with $135 million in branded sales. It is the first product that is generically equivalent to Mucinex® 600mg Extended-Release tablets. We launched the generic equivalents of Luxiq® Foam and Nicorette® mini lozenges and the authorized generic of Acetadote® injection. Finally, we filed an ANDA for the generic equivalent of Androgel® 1.62% and we believe we are the first to file. After the quarter ended, we closed our acquisition of Velcera, further expanding our recent entry into companion animal health and broadening our product offering. All of these great milestones were achieved while expanding margins in a record sales quarter.”
Key Stats (on next page)…
Revenue increased 4.17% from $882.96 million in the previous quarter. EPS increased 4.41% from $1.36 in the previous quarter.
Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a profit of $1.51 to a profit $1.57. For the current year, the average estimate has moved up from a profit of $5.56 to a profit of $5.64 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)